Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background & Aims</h3><p>Nonalcoholic fatty liver disease (NAFLD), especially the nonalcoholic steatohepatitis (NASH), have become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury and different degrees of fibrosis. However, there is no FDA‐approved medication to treat this devastating disease. Therapeutic activators of the AMP‐Activated Protein Kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine <i>Cordyceps militaris</i>, has recently emerged as a promising drug candidate for metabolic diseases. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach & Results</h3><p>We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation‐dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be a novel AMPK activator that can be used for the treatment of NASH.</p></section>

Discovery of Oral AMP-Activated Protein Kinase Activators for Treating Hyperlipidemia

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Discovery of natural adenosine monophosphate‐activated protein kinase activators through virtual screening and activity verification studies

Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators.

AMPK activator C24 inhibits hepatic lipogenesis and ameliorates dyslipidemia in HFHC diet-induced animal models

In Silico Design for Adenosine Monophosphate-Activated Protein Kinase Agonist from Traditional Chinese Medicine for Treatment of Metabolic Syndromes.

Novel Small-Molecule Ampk Activator Orally Exerts Beneficial Effects on Diabetic Db/Db Mice

Computer-aided drug design for AMP-activated protein kinase activators.

In Silico Analysis of AMP-activated Protein Kinase and Ligand-based Virtual Screening for Identification of Novel AMPK Activators.

Discovery of a natural small-molecule AMP-activated kinase activator that alleviates nonalcoholic steatohepatitis

Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway

Drug Design for AMP-Activated Protein Kinase Agonists in Silico

Study of Amp-Activated Protein Kinase Agonists by Structure-Based Drug Designing

Vascular adenosine monophosphate-activated protein kinase: Enhancer, brake or both?

Ginsenoside Rh4 prevents endothelial dysfunction as a novel AMPK activator

Targeting AMPK signalling pathway with natural medicines for atherosclerosis therapy: an integration of in silico screening and in vitro assay

Computational screening and QSAR analysis for design of AMP-activated protein kinase agonist

Imidazo[1,2‐a]pyridine Derivatives as AMPK Activators: Synthesis, Structure–Activity Relationships, and Regulation of Reactive Oxygen Species in Renal Fibroblasts

Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products

Association Between Expression of AMPK Pathway and Adiponectin, Leptin, and Vascular Endothelial Function in Rats with Coronary Heart Disease.